Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
While battling glioblastoma, Eric Smith feared he wouldn’t get to see his daughter grow up. He’s had the chance thanks to a clinical trial.
Health equity advocate Karen Winkfield, MD, MPH, works to enroll more underserved people with cancer in lifesaving clinical trials.
Study finds that ide-cel produces remissions in almost 75% of patients with multiple myeloma who had relapsed after previous treatments.
I’ve been extremely fortunate to go more than five years longer than the average time on the drug I’m taking. But now things have changed.
Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.
Experimental monoclonal antibody sotigalimab shows promising results in a Phase I study.
Researchers report that a personalized cancer vaccine called NeoVax may work to keep melanoma at bay
Eventual vaccination of children will be crucial to subduing the COVID virus, but pediatricians are split on how fast to move toward that.
The Senate-passed bill memorializing Henrietta Lacks aims to address underrepresentation in cancer clinical trials.
Keesha Sharp has a message of hope about new research for people with pancreatic cancer.
Researchers at the annual Society for the Immunotherapy for Cancer reported on melanoma clinical trial results from this year.
Despite being the only current cure for MDS, transplants generally haven’t been offered to older patients.
Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.